Janssen Launches Phase 3 Invokana Trial in Diabetic Nephropathy Janssen announced the availability of Invega Trinza (paliperidone palmitate) extended-release injectable suspension for the treatment of ...
Tanara never thought she’d be where she is today. Leading up to and following her diagnosis with schizophrenia, she often felt alone — her symptoms led her to isolate herself from her friends, family, ...
This leaflet answers some of the common questions about Invega Trinza. It does not contain all of the available information. It does not take the place of talking to your doctor or pharmacist. If you ...
The FINANCIAL — The first schizophrenia treatment to be taken just four times a year – with dosing measured in seasons, not days – is now available in the United States. The three-month dosing ...
Janssen Pharmaceuticals, Inc., a member of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the US Food and Drug Administration (FDA) approved under priority review the New ...
Johnson & Johnson's ($JNJ) once-a-month antipsychotic med Invega Sustenna is already raking in blockbuster numbers, but the company is eyeing even bigger sales for ...
TITUSVILLE, N.J., May 19, 2015 / PR Newswire / — There's a new treatment option for schizophrenia – INVEGA TRINZA™ (three-month paliperidone palmitate), the first and only schizophrenia medication to ...
Invega Hafyera is the third drug in Johnson & Johnson's Invega franchise to be approved, joining the monthly Invega Sustenna and quarterly Invega Trinza. Based on Invega Hafyera's similar efficacy to ...
TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback